Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials (Advances in Therapy, (2017), 34, 6, (1327-1339), 10.1007/s12325-017-0521-z);Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials

Advances in Therapy

Volumn 34, Issue 6, 2017, Pages 1327-1339

  Adsit, Sandra ^a   Zaldivar, Enrique Rivas ^b   Sofen, Howard ^c   Dei Cas, Ignacio ^d   Maldonado García, César ^e   Peñaranda, Elkin O ^f   Puig, Luís ^g   Meng, Xiangyi ^h   Fox, Todd ^h   Guana, Adriana ^h  

^a TCR Medical Corporation   (United States)

^b Dermos   (Guatemala)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HALITUS   (Argentina)

^e CENTRO DERMATOLÓGICO DR LADISLAO DE LA PASCUA   (Mexico)

^f Riesgo de Fractura CAYRE IPS   (Colombia)

^g UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^h NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Biologic therapy; Dermatology Life Quality Index; Hispanic; IL 17; Moderate to severe psoriasis; Non Hispanic; Pooled analysis; Psoriasis Area and Severity Index; Secukinumab; Subcutaneous injection

Indexed keywords

ETANERCEPT; SECUKINUMAB; MONOCLONAL ANTIBODY;

ABDUCENS NERVE PARALYSIS; ACUTE CHOLECYSTITIS; ADULT; ARTICLE; BRAIN ISCHEMIA; CHOLELITHIASIS; CLAVICLE FRACTURE; COMPARATIVE EFFECTIVENESS; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ETHNIC DIFFERENCE; FEMALE; HISPANIC; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL (TOPIC); PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; THYROID CANCER; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; UTERUS MYOMA; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; PHASE 3 CLINICAL TRIAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; DOUBLE-BLIND METHOD; ETANERCEPT; FEMALE; HISPANIC AMERICANS; HUMANS; MALE; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85017237972     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-017-0563-2     Document Type: Erratum

References (17)

1. Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology. 2014;141:133–42.
2. Blauvelt A, Prinz JC, Gottlieb AB, et al. Secukinumab administration by pre-filled syringe: efficacy, safety, and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172:484–93.
3. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371:326–38.
4. Paul C, Lacour JP, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29:1082–90.
5. Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373:1329–39.
6. McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386:1137–46.
7. Cosentyx (secukinumab) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2015.
8. Cosentyx (secukinumab) [summary of product characteristics]. Camberley, UK: Novartis Europharm Limited. European Medicines Agency.
9. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM, Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–85.
10. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70:512–6.
11. Davis SA, Narahari S, Feldman SR, Huang W, Pichardo-Geisinger RO, McMichael AJ. Top dermatologic conditions in patients of color: an analysis of nationally representative data. J Drugs Dermatol. 2012;11:466–73.
12. Ennis SR, Rios-Vargas M, Albert NG. The Hispanic population: 2010 census briefs. 2011. http://www.census.gov/prod/cen2010/briefs/c2010br-04.pdf. Accessed 8 July 2016.
13. Shah SK, Arthur A, Yang YC, Stevens S, Alexis AF. A retrospective study to investigate racial and ethnic variations in the treatment of psoriasis with etanercept. J Drugs Dermatol. 2011;10:866–72.
14. Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator’s Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatol Treat. 2015;26:23–31.
15. Katugampola RP, Lewis VJ, Finlay AY. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol. 2007;156:945–50.
16. Spelman LJ, Blauvelt A, Loffler J, Papavassilis C, Fox T. Secukinumab shows efficacy regardless of baseline disease severity in subjects with moderate to severe plaque psoriasis: a pooled analysis from four phase 3 studies. In: Presented at the annual European academy of dermatology and venereology, Amsterdam, the Netherlands, 8–12 Oct 2014.
17. Taylor P, Hugo Lopez M, Martínez J, Velasco G. When labels don’t fit: Hispanics and their views of identity. 2012. http://www.pewhispanic.org/2012/04/04/when-labels-dont-fit-hispanics-and-their-views-of-identity/. Accessed 8 July 2016.